Skip to content
thestock.space

On 6 Nov 2026, Eris Lifesciences was priced at ₹1,234.10, or 24.0× trailing earnings, against an industry P/E of 28.7×, and the shares are 29% below their 52-week high. Sales and net profit grew 23% and 17% a year over 3 years, with ROCE of 16% and ROE of 19%. Debt is 0.59× equity, and its dividend yield is 1.2%. It is a small-cap company with a market cap of ₹17,122 Cr, ranked 26th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 23% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,234.70
Day high
₹1,237.90
Day low
₹1,216.10
Prev. close
₹1,229.90
Volume
44.7K

Health check

3 good · 2 fair · 1 to check
  • ReturnsBehind

    −23.2% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 24.0 vs industry 28.7.

  • GrowthStrong

    Sales +23.3%, profit +17.5% a year over 3 years.

  • ProfitabilityAverage

    ROCE 15.7% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.59× equity, interest covered 4.3×, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹17,122 Cr, #26 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹3,312 Cr · profit ₹708 Cr
Market cap
₹17,122 Cr
Small cap
P/E
24.0
Industry 28.7
Price to book
4.13
Peers 4.99
Dividend yield
1.17%
ROE
18.8%
Peers 14.7%
ROCE
15.7%
Peers 17.9%
Debt to equity
0.59
Debt ₹2,430 Cr
EPS (TTM)
₹51.42
Face value ₹1
OPM (TTM)
35.1%
Net margin 21.4%
Sales growth
+12.6%
Latest quarter vs a year ago
Profit growth
+52.9%
Latest quarter vs a year ago
Price to sales
5.17
EV/EBITDA 16.8

Strengths and risks

Strengths

  • Return on equity of 18.8%.
  • Quarterly profit up 52.9% on a year ago.
  • Net margin of 21.4%.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, GLP-1, and vitamins/minerals/nutrients. It also…

Headquarters
Ahmedabad
Employees
2,758
Sector
Healthcare
ISIN
INE406M01024
Website
eris.co.in

Price range

52 weeks

₹1,069.00₹1,740.00

Today

₹1,216.10₹1,237.90
Avg volume (3M)
1 L
1-year return
minus 23.2%
From 52-week high
minus 29.1%

Analyst consensus

10 analysts
Strong buyMean target ₹1,514.40 plus 22.7%

Target range, with today’s price

Low ₹1,140.00High ₹1,780.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
ERISEris Lifesciences1,234.10plus 0.34%17,12224.04.1315.7%18.8%35.1%23.3%17.5%1.17%minus 23.2%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
790801752869890
502519479573580
288282274296309
36.5%35.2%36.4%34.1%34.8%
3.10.10.922.3
49.648.845.646.746.4
69.170.369.672.173.4
–−17.2––−35.9
173145159179156
22.1%25.1%−75.1%20.2%−20.0%
12099.7282142184
8.817.3220.5710.2613.25

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+23.3%
Profit CAGR 3Y
+17.5%
EPS CAGR 3Y
+17.3%
ROE
18.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,6621,9912,8793,115
–+19.8%+44.6%+8.2%
1,1231,3131,8611,994
5396781,0191,121
32.5%34.0%35.4%36.0%
3.51413.86.5
26.284.8231193
117183315279
5.16.73.1−16.6
405431489639
7.5%7.9%23.4%−1.4%
382392352620
–+2.6%minus 10.3%+76.1%
28.0728.7925.8145.26

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
13.613.613.613.9
2,1822,5732,8413,889
8772,7812,4782,359
5951,6731,7041,104
3,6677,0407,0367,366
389569756981
33.229.693.8273
6.915.710.710.5
861,33920555.4
3,1525,0885,9716,045
3,6677,0407,0367,366

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2924861,065538
−982−1,855−80−369
6881,380−881−314
−2.311.3104−145
−841−129−155−297
−550357910241
−99.9–−100–

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 22.3% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you